Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by Dacoltson Feb 15, 2007 10:32pm

407 Views

Post# 12247658

RE: The ship is sailing

We are going to need our volume to pick up with we are going to even sniff $30 tomorrow. I personally don't think we are as close as some think to the buyout. To be honest with you, I would rather the companies battle it out for awhile for NEXVAS. The end game will need to come sometime in March for the Resverlogix employees to get their 5 million in bonuses. Let's get some volume!!

Bullboard Posts

Debt-free cannabis company set for next stage of growth